260 completed. 260 Phase 2, 30 Phase 3, 24 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 260 | Completed 260 |
| Phase 3 | 30 | Completed 30 |
| Phase 1 | 24 | Completed 24 |
Follow Hyperlipidemias: new trials by email Literature Review of Hyperlipidemias trials Research Report on Hyperlipidemias
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Safety, Efficacy of SYH2053 in Chinese Participants With Non-familial Hypercholesterolemia and Mixed Hyperlipidemia SYH2053/placebo injection, Inclisiran (Leqvio®) 300mg - Hypercholesterolemia and Mixed Hyperlipidemia | Phase 2 | Completed | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | 156 | 2024-12-03 | 2026-02-19 |
| Effects of RDX-002 on Postprandial Triglycerides in Patients Discontinuing GLP-1 Agonists RDX-002, Placebo - Triglycerides, Weight Gain Trajectory | Phase 2 | Completed | Response Pharmaceuticals | 68 | 2024-09-27 | 2026-07-02 |
| A Phase II Study to Evaluate the Efficacy and Safety of of DR10624 in Subjects With Severe Hypertriglyceridemia DR10624 Injection, Placebo - Severe Hypertriglyceridemia | Phase 2 | Completed | Zhejiang Doer Biologics Co., Ltd. | 79 | 2024-08-01 | 2026-01-13 |
| Efficacy and Safety of SHR-1918 in Patients With Hyperlipidemia SHR-1918; SHR-1918 Placebo - Hyperlipidemia | Phase 2 | Completed | Beijing Suncadia Pharmaceuticals Co., Ltd | 44 | 2024-07-02 | 2026-02-05 |
| Evaluate the Efficacy and Safety of SHR-1918 in Patients With Homozygous Familial Hypercholesterolemia SHR-1918 - Homozygous Familial Hypercholesterolemia | Phase 2 | Completed | Beijing Suncadia Pharmaceuticals Co., Ltd | 26 | 2023-12-22 | 2025-09-05 |
| Study of MAR001 in Adults With Metabolic Dysfunction MAR001, Placebo - Hypertriglyceridemia | Phase 1 / Phase 2 | Completed | Marea Therapeutics | 55 | 2023-07-22 | 2025-11-13 |
| Study of the Efficacy and Safety of NST-1024 Versus Placebo in Subjects With Hypertriglyceridemia NST-1024, Placebo - High Triglycerides | Phase 2 | Completed | NorthSea Therapeutics B.V. | 50 | 2023-06-30 | 2025-04-24 |
| A Phase II Study to Evaluate the Safety and Efficacy of SAL003 Combined With Atorvastatin in Hypercholesterolemia and Mixed Dyslipidemia SAL003 140mg+Atorvastatin, SAL003 420mg+Atorvastatin, Placebo 140mg+Atorvastatin - Hypercholesterolemia and Mixed Dyslipidemia | Phase 2 | Completed | Shenzhen Salubris Pharmaceuticals Co., Ltd. | 214 | 2023-06-02 | 2025-12-12 |
| Study of HSK31679 in Subjects With Hypercholesterolemia With Nonalcoholic Fatty Liver Disease(NAFLD) HSK31679 low dose, HSK31679 medium dose, HSK31679 high dose - Hypercholesterolemia | Phase 2 | Completed | Haisco Pharmaceutical Group Co., Ltd. | 210 | 2023-04-26 | 2024-04-09 |
| A Clinical Study in Children With Heterozygous Familial Hypercholesterolemia (HeFH) Aged 6 to 17 Treated Once Daily With Bempedoic Acid Oral Dosing (CLEAR Path 1) Bempedoic acid - Hypercholesterolemia | Phase 2 | Completed | Esperion Therapeutics, Inc. | 31 | 2023-01-12 | 2026-07-17 |
| A Study of LY3473329 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular Events LY3473329, Placebo - Lipoprotein Disorder | Phase 2 | Completed | Eli Lilly and Company | 233 | 2022-11-24 | 2025-03-25 |
| A Study of LY3561774 in Participants With Mixed Dyslipidemia LY3561774, Placebo - Dyslipidemias, Lipid Metabolism Disorders | Phase 2 | Completed | Eli Lilly and Company | 205 | 2022-07-20 | 2025-03-17 |
| A Dose-Finding Study in Japanese Patients to Evaluate the Effect of Obicetrapib as an Adjunct to Stable Statin Therapy. Obicetrapib, Placebo - Dyslipidemia, Hypercholesterolemia | Phase 2 | Completed | NewAmsterdam Pharma | 102 | 2022-06-27 | 2024-10-29 |
| A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Adults With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease (Established or at Increased Risk for), and/or With Severe Hypertriglyceridemia Olezarsen, Placebo - Hypertriglyceridemia, Atherosclerotic Cardiovascular Disease | Phase 2 | Completed | Ionis Pharmaceuticals, Inc. | 154 | 2022-05-09 | 2026-04-23 |
| A Study of the Efficacy and Safety of Enclitide Chloride (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-008) Enclitide Chloride, Placebo - Hypercholesterolemia, Familial Hypercholesterolemia | Phase 2 | Completed | Merck Sharp & Dohme LLC | 381 | 2022-03-10 | 2024-12-09 |
| Study to Evaluate the Effect of Obicetrapib in Combination With Ezetimibe as an Adjunct to HIS Therapy Obicetrapib, Ezetimibe 10mg, Obicetrapib placebo - Dyslipidemias, High Cholesterol | Phase 2 | Completed | NewAmsterdam Pharma | 119 | 2022-03-09 | 2024-07-03 |
| Supplementation of Oil Palm Phenolics to Improve Lipid Profile in Subjects With Minor Hyperlipidaemia Placebo, 250 mg OPP - Hyperlipidemias, Hypercholesterolemia | Phase 2 | Completed | Isa Naina Mohamed | 50 | 2021-10-18 | 2022-04-13 |
| A Study to Assess the Safety, Efficacy and Tolerability of AZD8233 Treatment in Participants With Hyperlipidaemia AZD8233, Placebo - Hyperlipidaemia | Phase 2 | Completed | AstraZeneca | 411 | 2021-07-07 | 2023-12-15 |
| Study to Evaluate ARO-APOC3 in Adults With Severe Hypertriglyceridemia ARO-APOC3, Placebo - Severe Hypertriglyceridemia | Phase 2 | Completed | Arrowhead Pharmaceuticals | 229 | 2021-05-31 | 2026-03-24 |
| Supplements, Placebo, or Rosuvastatin Study Fish Oil, Cinnamon, Garlique,Turmeric, Plant Sterol, Red Yeast Rice, Rosuvastatin, Placebo - Hypercholesterolemia | Phase 2 | Completed | The Cleveland Clinic | 203 | 2021-04-23 | 2023-05-25 |
Showing 20 of 260. Sign in to see all of them.
Hypercholesterolemia (122) · Hypertriglyceridemia (58) · Dyslipidemias (39) · Cardiovascular Diseases (22) · Hyperlipoproteinemia Type II (22) · Hypertension (15) · Metabolic Syndrome (15) · Diabetes Mellitus (14) · Atherosclerosis (12) · Homozygous Familial Hypercholesterolemia (12) · Lipid Metabolism Disorders (12) · Obesity (12) · Insulin Resistance (11) · Metabolic Diseases (11)
Nutritional and Metabolic Diseases (259) · Metabolic Diseases (249) · Lipid Metabolism Disorders (248) · Dyslipidemias (221) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (37) · Genetic Diseases, Inborn (34) · Lipid Metabolism, Inborn Errors (33) · Glucose Metabolism Disorders (32) · Metabolism, Inborn Errors (32) · Hyperlipoproteinemias (31) · Vascular Diseases (30) · Pathological Conditions, Signs and Symptoms (27) · Cardiovascular Diseases (24) · Endocrine System Diseases (21)
Atorvastatin (29) · Ezetimibe (16) · Fenofibrate (11) · 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid (10) · evolocumab (10) · Hydroxymethylglutaryl-CoA Reductase Inhibitors (8) · Rosuvastatin Calcium (8) · alirocumab (8) · gemcabene (7) · mipomersen (7) · BMS201038 (5) · Fish Oils (5) · Pravastatin (5) · ALN-PCS (4) · Exercise (4)
Esperion Therapeutics, Inc. (10) · Amgen (9) · Kastle Therapeutics, LLC (7) · University of Toronto (7) · AstraZeneca (6) · Merck Sharp & Dohme LLC (6) · NeuroBo Pharmaceuticals Inc. (6) · Regeneron Pharmaceuticals (6) · Aegerion Pharmaceuticals, Inc. (5) · Eli Lilly and Company (5) · National Heart, Lung, and Blood Institute (NHLBI) (5) · Novartis Pharmaceuticals (5) · Pfizer (5) · Sanofi (5) · University Health Network, Toronto (5)
United States (131) · Canada (72) · Netherlands (30) · China (17) · Germany (15) · Japan (15) · Australia (14) · Denmark (14) · Hungary (12) · Czechia (11) · Italy (11) · France (10) · Poland (10) · Spain (10) · United Kingdom (10)
Jean-Claude Tardif, MD (4) · David JA Jenkins, MD, PhD, DSc (3) · David Crowley, MD (2) · Eli Roth, MD (2) · Gary F Lewis, MD (2)
PMID 30183102, PMID 37994400, PMID 22301925, PMID 26872608, PMID 34677608, PMID 20707601, PMID 21518985, PMID 24014831, PMID 25060413, PMID 25091629, PMID 25660356, PMID 28181260, PMID 28324110, PMID 29037448, PMID 31194872, PMID 33990512, PMID 34223895, PMID 38018702, PMID 38415744, PMID 11914243, PMID 12221048, PMID 12805393, PMID 16996859, PMID 17030154, PMID 17215532, PMID 17298834, PMID 17325296, PMID 17384435, PMID 17392721, PMID 17434849, PMID 17556685, PMID 17563345, PMID 17971707, PMID 17987126, PMID 18018771, PMID 19364997, PMID 19500003, PMID 19506174, PMID 19592624, PMID 19727665, PMID 19810001, PMID 19843338, PMID 20008831, PMID 20220185, PMID 20378080, PMID 20428452, PMID 20435205, PMID 20527967, PMID 20660224, PMID 20668250
2016 (4), 2005 (2), 2015 (1), 2017 (1), 2019 (1), M01RR000096 (1), M01RR000334 (1), R01DK058785 (1), R01DK088114 (1), R01HL042554 (1), R01HL057354 (1), R01HL070742 (1), R21AG023805 (1), U01HL044315 (1)